Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

JAK1 Activators

JAK1, or Janus kinase 1, is a member of the Janus kinase family of intracellular non-receptor tyrosine kinases. It serves as a critical component of various signaling pathways, particularly those mediated by cytokine receptors. These receptors, upon ligand binding, undergo conformational changes that activate associated JAKs. Upon activation, JAK1 phosphorylates tyrosine residues on the receptor, creating docking sites for downstream signaling molecules such as signal transducers and activators of transcription (STATs). Subsequently, STAT proteins are recruited to the activated receptor complex, where they are phosphorylated by JAK1. Once phosphorylated, STATs dimerize, translocate to the nucleus, and regulate the transcription of target genes involved in diverse cellular processes, including cell proliferation, differentiation, and immune responses.

Activation of JAK1 typically occurs in response to extracellular stimuli, such as cytokines, growth factors, and hormones, that bind to their respective receptors on the cell surface. Upon ligand binding, receptor-associated JAK1 is brought into close proximity, leading to trans-phosphorylation and activation of JAK1 kinase activity. This results in the propagation of downstream signaling cascades through phosphorylation of cytoplasmic substrates, such as STAT proteins. Additionally, activated JAK1 can also phosphorylate and activate other signaling molecules, including phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK), contributing to the complexity and versatility of cellular responses mediated by JAK1-dependent pathways. Overall, the activation of JAK1 is tightly regulated and serves as a crucial step in transducing extracellular signals into intracellular responses essential for various physiological processes.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib activates JAK1 indirectly by inhibiting multiple receptor tyrosine kinases, including VEGFR, PDGFR, and RAF, leading to JAK1 activation.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

Ruxolitinib directly activates JAK1 by binding to its ATP-binding site, resulting in conformational changes that enhance its kinase activity.

Tyrphostin B42

133550-30-8sc-3556
5 mg
$26.00
4
(1)

Tyrphostin B42 (AG-490) activates JAK1 indirectly by inhibiting the activity of the upstream kinase, JAK2, leading to enhanced activation of JAK1.

Baricitinib

1187594-09-7sc-364730
sc-364730A
5 mg
25 mg
$200.00
$664.00
(1)

Baricitinib activates JAK1 by binding to the ATP-binding pocket of JAK1, promoting its phosphorylation and subsequent activation.

Fludarabine

21679-14-1sc-204755
sc-204755A
5 mg
25 mg
$58.00
$204.00
15
(1)

Fludarabine indirectly activates JAK1 by inhibiting adenosine deaminase, leading to accumulation of adenosine, which activates JAK1 signaling.

Curcumin

458-37-7sc-200509
sc-200509A
sc-200509B
sc-200509C
sc-200509D
sc-200509F
sc-200509E
1 g
5 g
25 g
100 g
250 g
1 kg
2.5 kg
$37.00
$69.00
$109.00
$218.00
$239.00
$879.00
$1968.00
47
(1)

Curcumin activates JAK1 indirectly by inhibiting NF-κB, a negative regulator of JAK1, resulting in enhanced JAK1 activation.

Piceatannol

10083-24-6sc-200610
sc-200610A
sc-200610B
1 mg
5 mg
25 mg
$51.00
$71.00
$199.00
11
(2)

Piceatannol activates JAK1 by directly binding to its SH2 domain, promoting its dimerization and subsequent activation.

Betulinic Acid

472-15-1sc-200132
sc-200132A
25 mg
100 mg
$117.00
$344.00
3
(1)

Betulinic acid activates JAK1 indirectly by inhibiting proteasomal degradation of JAK1, leading to its accumulation and activation.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

EGCG activates JAK1 indirectly by inhibiting protein tyrosine phosphatases, which dephosphorylate and inactivate JAK1, leading to its activation.